Research presentation·October 2026
106 days from Brussels
What the data reveals about Europe’s clinical trial timelines, research competitiveness and the implications for country selection.
Zina SarifFounder & CEO, YendouFree access
Get the full presentation
Explore the analysis and charts. View online or download the PDF.
Access granted
Your presentation is open
It has opened in a new tab. If it did not, use the button below.
Open the presentationInteractive, 55 steps Download the presentationPDF, 5 MBInside the presentation
Four chapters, from the promise the Regulation made to what it now costs Europe.
01
The promise
One application, one portal, one decision. The clock the law wrote in 2014, and the loopholes it wrote into itself.
02
The clock
What the public register shows about how long authorisation really takes, and how Europe compares.
03
The market
Commercial trials, Phase I and the hubs Europe lost while other regions grew.
04
The consequence
The value, the jobs and the patient places at stake, and the reforms on the table.
The findings
In 2014 Brussels promised one application, one portal, one decision, and a more attractive Europe for clinical research. The presentation tests both promises against the public CTIS register.
days to a decision when the sponsor gets no questions, as the Regulation wrote it.
days, the median the EMA reports today, above the 106-day legal maximum with one round of questions.
Europe’s share of global commercial trials, from 2013 to 2023.
a year that industry trials add to the EEA economy, the value at stake.
Sources as cited in the presentation: CTIS public register, EMA, EFPIA and Frontier Economics.